Wednesday, July 30, 2014
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Merck to pay $3.85B for hepatitis C drug developer

Merck

FILE - This Thursday, Feb. 28, 2013 file photo shows a patch with the Merck logo on a scientist's lab coat in West Point, Pa. Merck on Monday, June 9, 2014 announced it will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer’s latest closing price. (AP Photo/Matt Rourke, File)

By
June 10, 2014 |

TRENTON, N.J. — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals.

Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. is already raking in billions of dollars from its groundbreaking new drug, Sovaldi.

Merck, based in Whitehouse Station, New Jersey, said it will spend $24.50 in cash for each Idenix share. Idenix closed at $7.23 on Friday, then more than tripled at Monday’s opening bell.

The boards of both companies have approved the deal, which should close in the third quarter.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in (certain) technologies,” Merck’s research head, Dr. Roger Perlmutter, said in a statement.

Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It’s in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs, known as IDX21437 and IDX21459, are in a class called nucleotide prodrugs, which stop the virus from producing genetic material needed to copy itself.

Merck has been testing two drugs together, MK-5172 and MK-8742, that the Food and Drug Administration has deemed a breakthrough therapy. Merck will soon start late-stage testing of the two drugs together and presumably will study them in combinations with the Idenix drugs.

About 4.4 million Americans and an estimated 170 million people worldwide have chronic hepatitis C, the leading cause of liver cancer and, in wealthy countries, the top reason for liver transplants. In the U.S., it kills more than 16,000 people a year.

While most people infected don’t know it because there are no obvious symptoms, a growing number have been identified and started treatment in the last few years as more effective medicines have been approved. That number is expected to grow as the U.S. population ages and patients infected decades ago through intravenous drug use, or from blood transfusions before the early 1990s, are diagnosed.

Merck has been a major player in hepatitis C since acquiring Schering-Plough in 2009. Back then, treatment was limited to twice-a-day pills called ribavirin and self-injections of a long-acting, synthetic form of immune system protein interferon. Treatment often lasted 48 weeks, only about 40 percent of patients were cured, and flu-like symptoms and other side effects of the interferon kept many patients from completing treatment.

In 2011, the FDA approved two drugs in a class called protease inhibitors, Merck’s Victrelis and Incivek from Vertex Pharmaceuticals. Those are taken with ribavirin and interferon, work by blocking an enzyme needed for copying the virus, and boost the cure rate to about 75 percent. But they require patients to take a dozen pills a day, and still endure flu-like side effects.

Last December, the FDA approved Gilead’s once-a-day pill Sovaldi, which cures 80 percent to 90 percent of patients, without the interferon injections and side effects.

Physicians quickly embraced it, and Sovaldi racked up more than $2 billion in sales in its first full quarter on sale, considered the best new drug launch in history. That’s mainly because of Sovaldi’s high price, about $1,000 per pill, or $84,000 for a 12-week treatment course, which continues to draw criticism from patients, insurers and government.

Sovaldi appears poised to dominate the hepatitis C market, greatly outselling Johnson & Johnson’s Olysio, approved about the same time. But there’s plenty of room for Merck and others because Sovaldi can’t be taken by some patients with multiple illnesses or certain hepatitis C subtypes.

In afternoon trading, Idenix shares climbed $16.76 to $23.99. Merck shares slipped 5 cents to $57.80.

Shares of another hepatitis C drug developer, Achillion Pharmaceuticals Inc., now seen as a potential takeover target, climbed 58 percent to $4.55.

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

Solano County Fair set to open Wednesday

By Ryan McCarthy | From Page: A1 | Gallery

 
Marketing study looks at Berryessa resorts

By Barry Eberling | From Page: A1, 2 Comments | Gallery

 
Library teens plan summer reading party

By Glen Faison | From Page: A3

Fairfield tries to end Cordelia Road detour

By Barry Eberling | From Page: A3, 15 Comments | Gallery

 
Caltrans makes I-80 lane change

By Barry Eberling | From Page: A3, 5 Comments

 
Police arrest suspected intruder

By Barry Eberling | From Page: A3, 6 Comments | Gallery

Activity is Medicine program coming to Suisun senior center

By Amy Maginnis-Honey | From Page: A3

 
 
Big-rig crash shuts down freeway onramp

By Amy Maginnis-Honey | From Page: A5, 2 Comments | Gallery

 
Big-rig driver strikes telephone lines in Fairfield

By Ryan McCarthy | From Page: A6, 5 Comments | Gallery

 
‘Guardians of the Galaxy’ primed for big screen

By Amy Maginnis-Honey | From Page: A7 | Gallery

 
Icon sends first A5 into the skies on maiden flight

By Susan Winlow | From Page: B7

Suisun City police log: July 28, 2014

By Glen Faison | From Page: A12

 
Fairfield police log: July 27, 2014

By Glen Faison | From Page: A12

Suisun City police log: June 27, 2014

By Glen Faison | From Page: A12

 
Fairfield police log: July 28, 2014

By Glen Faison | From Page: A12

Weather for Wedneday, July 30, 2014

By Daily Republic staff | From Page: B14

 
.

US / World

Hamas demands for cease-fire and Israel’s concerns

By The Associated Press | From Page: A1, 1 Comment

 
Israel hits symbols of Hamas rule; scores killed

By The Associated Press | From Page: A1

Fist bumps less germy than handshakes, study says

By The Associated Press | From Page: A2, 3 Comments | Gallery

 
New California fines for wasting water take effect

By The Associated Press | From Page: A5, 1 Comment

California lifeguard injured by lightning improves

By The Associated Press | From Page: A5

 
PG&E charged with obstruction over San Bruno blast

By The Associated Press | From Page: A5

Chevron California refinery overhaul up for vote

By The Associated Press | From Page: A5

 
Crews make gains on 2 California wildfires

By The Associated Press | From Page: A8 | Gallery

Tuberculosis patient who refused care is arrested

By The Associated Press | From Page: A8 | Gallery

 
4 charged with murder in death of USC student

By The Associated Press | From Page: A8

Last crew member of Enola Gay dies in Georgia

By The Associated Press | From Page: A9

 
Poll: Immigration concerns rise with tide of kids

By The Associated Press | From Page: A9 | Gallery

Shelling adds to mounting civilian toll in Ukraine

By The Associated Press | From Page: A10

 
US, Europe impose tough new sanctions on Russia

By The Associated Press | From Page: A10 | Gallery

Generation of tanners see spike in deadly melanoma

By The Associated Press | From Page: A12, 1 Comment

 
Senate confirms McDonald as VA secretary

By The Associated Press | From Page: A12 | Gallery

Body of young stowaway found in US cargo plane

By The Associated Press | From Page: A12

 
Report: Health premiums rose significantly in 2014

By The Associated Press | From Page: A12, 1 Comment

Highway, bridge money at risk: Senate to vote

By The Associated Press | From Page: A12

 
Senate bill would end NSA phone records collection

By The Associated Press | From Page: A12

Liberians in US worry about Ebola outbreak

By The Associated Press | From Page: A13

 
Top doctor dies from Ebola after treating dozens

By The Associated Press | From Page: A13, 1 Comment

.

Opinion

Red light camera fate now uncertain in state

By Thomas Elias | From Page: A11

 
Obscure state agency creates big money problems

By Dan Walters | From Page: A11

Some people have missed the drought memo

By Letter to the Editor | From Page: A11, 17 Comments

 
What kids don’t know would shock you

By Letter to the Editor | From Page: A11, 34 Comments

 
Cemetery support committee thanks sponsors

By Letter to the Editor | From Page: A11

.

Living

Today in History for July 30, 2014

By The Associated Press | From Page: A2

 
Community Calendar: July 30, 2014

By Susan Hiland | From Page: A2

What to do when ‘it’ hits the fan

By Barton Goldsmith | From Page: A2

 
Horoscopes for July 30, 2014

By Holiday Mathis | From Page: B5

I like Liam, but I think he’s interested in another girl

By Kathy Mitchell and Marcy Sugar | From Page: B5

 
A do-ahead dinner to make back-to-school smoother

By The Associated Press | From Page: B6

You too can bake artisanal quality bread at home

By Elizabeth Karmel | From Page: B6

 
A healthy afterschool snack that eats like a treat

By The Associated Press | From Page: B6

.

Entertainment

‘Sharknado’ sequel has bite and lots of laughs

By Frazier Moore | From Page: A7 | Gallery

 
TVGrid

By Daily Republic Syndicated Content | From Page: B7

Music aside, Queen of Soul is pumped for fair food

By The Associated Press | From Page: A7

 
Sarah Palin launches online subscription channel

By The Associated Press | From Page: A7, 2 Comments | Gallery

.

Sports

NCAA settles head-injury suit, will change rules

By The Associated Press | From Page: B1

 
49ers WR Brandon Lloyd enjoying return to NFL

By The Associated Press | From Page: B1

Schaub settles in as Raiders starting QB

By The Associated Press | From Page: B1 | Gallery

 
Fairfield Indians blank Next Level Athletic to win SRL tournament title

By Daily Republic staff | From Page: B1 | Gallery

 
Vin Scully to return for 66th season in LA in 2015

By The Associated Press | From Page: B2

Mudcats tie Vacaville Admirals

By Daily Republic staff | From Page: B2

 
No joke: Kings’ Cousins hopes for Team USA shot

By The Associated Press | From Page: B2 | Gallery

Liriano fans 11 in Pirates’ 3-1 win

By The Associated Press | From Page: B2

 
Athletics rally for 6 runs in 9th, beat Astros 7-4

By The Associated Press | From Page: B2 | Gallery

Husband arrested in death of NBA player’s aunt

By The Associated Press | From Page: B2

 
Triple-A brawl results in 11 suspensions

By The Associated Press | From Page: B2

Broken water main floods UCLA; 5 people rescued

By The Associated Press | From Page: B2

 
49ers sign former Cardinals RB Alfonso Smith

By The Associated Press | From Page: B2

 
This date in sports history for Wednesday, July 30, 2014

By The Associated Press | From Page: B3

.

Business

Study: 35 percent in US facing debt collectors

By The Associated Press | From Page: B7

 
McDonald’s could be liable for labor practices

By The Associated Press | From Page: B8

Food writers subpoenaed in ‘pink slime’ lawsuit

By The Associated Press | From Page: B8

 
Stocks end lower ahead of economic data

By The Associated Press | From Page: B8

Twitter 2Q results soar, stock flies high

By The Associated Press | From Page: B8

 
.

Obituaries

Jack L Hudack

By Nancy Green | From Page: A4

 
Robert Dale Myers Sr.

By Nancy Green | From Page: A4

Jeanetta M. Hale

By Nancy Green | From Page: A4

 
Patricia Jo McDonald

By Nancy Green | From Page: A4

.

Comics

Frank and Ernest

By Daily Republic Syndicated Content | From Page: B4

 
Sally Forth

By Daily Republic Syndicated Content | From Page: B4

Dilbert

By Daily Republic Syndicated Content | From Page: B4

 
Zits

By Daily Republic Syndicated Content | From Page: B4

Beetle Bailey

By Daily Republic Syndicated Content | From Page: B4

 
Get Fuzzy

By Daily Republic Syndicated Content | From Page: B4

Pickles

By Daily Republic Syndicated Content | From Page: B4

 
Baldo

By Daily Republic Syndicated Content | From Page: B4

Wizard of Id

By Daily Republic Syndicated Content | From Page: B4

 
Baby Blues

By Daily Republic Syndicated Content | From Page: B4

Peanuts

By Daily Republic Syndicated Content | From Page: B4

 
Rose is Rose

By Daily Republic Syndicated Content | From Page: B4

For Better or Worse

By Daily Republic Syndicated Content | From Page: B4

 
Garfield

By Daily Republic Syndicated Content | From Page: B4

Blondie

By Daily Republic Syndicated Content | From Page: B4

 
Crossword

By Daily Republic Syndicated Content | From Page: B5

Sudoku

By Daily Republic Syndicated Content | From Page: B5

 
Bridge

By Daily Republic Syndicated Content | From Page: B5

Word Sleuth

By Daily Republic Syndicated Content | From Page: B5

 
Cryptoquote

By Daily Republic Syndicated Content | From Page: B5